Country profiles for 22 high-burden countries
**Afghanistan**  
Population 2014  32 million

### Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>14 (10–18)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.067 (0.072–0.1)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>110 (56–180)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>60 (53–67)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>0.32 (0.25–0.4)</td>
</tr>
</tbody>
</table>

Case detection, all forms (%)

53 (47–60)

### Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>3.2 (2.3–4.1)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>750 (540–960)</td>
</tr>
</tbody>
</table>

**TB case notifications 2014**

<table>
<thead>
<tr>
<th>NEW*</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>14 737</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>8 573</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>7 227</td>
</tr>
<tr>
<td>Total new and relapse</td>
<td>31 746</td>
</tr>
</tbody>
</table>

Among 30 537 new cases:

4 454 (15%) cases aged under 15 years, male:female ratio: 0.7

### Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>2 (&lt;1%)</td>
<td>184 (8%)</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td></td>
<td>88</td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TB/HIV 2014

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>88</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>76</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>1 115</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>71</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>0</td>
</tr>
</tbody>
</table>

### Laboratories 2014

<table>
<thead>
<tr>
<th>NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population)</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
</tr>
<tr>
<td>Is second-line drug susceptibility testing available?</td>
</tr>
</tbody>
</table>

### Financing TB control 2015

<table>
<thead>
<tr>
<th>NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget (US$ millions)</td>
</tr>
<tr>
<td>% Funded domestically</td>
</tr>
<tr>
<td>% Funded internationally</td>
</tr>
<tr>
<td>% Unfunded</td>
</tr>
</tbody>
</table>

---

*Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

* Ranges represent uncertainty intervals

* Includes cases with unknown previous TB treatment history.

* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
Bangladesh  ■  Population 2014  159 million

**Estimates of TB burden**  2014

<table>
<thead>
<tr>
<th>Mortality (excludes HIV+TB)</th>
<th>81 (59–110)</th>
<th>51 (37–68)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.18 (0.14–0.22)</td>
<td>0.11 (0.09–0.14)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>640 (340–1 000)</td>
<td>404 (211–659)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>360 (320–410)</td>
<td>227 (200–256)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>0.57 (0.45–0.71)</td>
<td>0.36 (0.28–0.45)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>53 (47–60)</td>
<td></td>
</tr>
</tbody>
</table>

**Estimates of MDR-TB burden**  2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>1.4 (0.7–2.5)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>2 100 (1 000–3 700)</td>
</tr>
</tbody>
</table>

**TB case notifications 2014**

<table>
<thead>
<tr>
<th>NEW</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>106 767</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>42 832</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>37 406</td>
</tr>
</tbody>
</table>

Total new and relapse: 191 166
Previously treated, excluding relapses: 5 631
Total cases notified: 196 797

Among 187,005 new cases:
6 262 (3%) cases aged under 15 years; male:female ratio: 1.5

**Reported cases of RR-/MDR-TB 2014**

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>12 573 (12%)</td>
<td>4 959 (51%)</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>994</td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>945</td>
<td></td>
</tr>
</tbody>
</table>

**TB/HIV 2014**

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

**Treatment success rate and cohort size**

<table>
<thead>
<tr>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>(93)</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>(86)</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>(75)</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>(72)</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>(25)</td>
</tr>
</tbody>
</table>

**Laboratories 2014**

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population)</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
</tr>
<tr>
<td>Is second-line drug susceptibility testing available?</td>
</tr>
</tbody>
</table>

**Financing TB control 2015**

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget (US$ millions)</td>
</tr>
<tr>
<td>% Funded domestically</td>
</tr>
<tr>
<td>% Funded internationally</td>
</tr>
<tr>
<td>% Unfunded</td>
</tr>
</tbody>
</table>

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Ranges represent uncertainty intervals. A joint reassessment of estimates of TB disease burden will be undertaken following completion of the national TB prevalence survey.

Includes cases with unknown previous TB treatment history.

Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

For more detailed information, please refer to the full report.
### Brazil

**Population 2014**: 206 million

---

#### Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>5.3 (4.9–5.7)</td>
<td>2.6 (2.4–2.7)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>2.4 (1.8–3.2)</td>
<td>1.2 (0.87–1.6)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>110 (51–180)</td>
<td>52 (25–89)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>90 (86–95)</td>
<td>44 (42–46)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>16 (14–17)</td>
<td>7.6 (6.9–8.4)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>82 (78–86)</td>
<td></td>
</tr>
</tbody>
</table>

#### Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>1.4 (1–1.8)</td>
<td>7.5 (5.7–9.9)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>820 (590–1,100)</td>
<td>950 (720–1,300)</td>
</tr>
</tbody>
</table>

#### TB case notifications 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>41,120</td>
<td>3,602</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>17,801</td>
<td>1,488</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>9,479</td>
<td>480</td>
</tr>
</tbody>
</table>

**Total new and relapse**: 73,970

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously treated, excluding relapses</td>
<td>7,542</td>
</tr>
<tr>
<td><strong>Total cases notified</strong></td>
<td>81,512</td>
</tr>
</tbody>
</table>

Among 73,970 new and relapse cases:

- 2,368 (3%) cases aged under 15 years; male:female ratio: 2.1

#### Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>15,344</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>702</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>702</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### TB/HIV 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
<td>56,981 (70)</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
<td>9,578 (17)</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
<td></td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
<td></td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
<td>37,540</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
<td></td>
</tr>
</tbody>
</table>

#### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>(%) COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>76,543 (72)</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>6,945 (38)</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>9,460 (46)</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>825 (51)</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>24 (25)</td>
</tr>
</tbody>
</table>

#### Laboratories 2014

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100,000 population)</td>
<td>1.6</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
<td>7.9</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
<td>0.6</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
<td>48</td>
</tr>
</tbody>
</table>

Is second-line drug susceptibility testing available? Yes, in country

#### Financing TB control 2015

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget (US$ millions)</td>
<td>77</td>
</tr>
<tr>
<td>% Funded domestically</td>
<td>72%</td>
</tr>
<tr>
<td>% Funded internationally</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>% Unfunded</td>
<td>27%</td>
</tr>
</tbody>
</table>

---

Data as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

* Ranges represent uncertainty intervals

* Includes cases with unknown previous TB treatment history

* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB

---

Data for all years can be downloaded from [www.who.int/tb/data](http://www.who.int/tb/data)
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Ranges represent uncertainty intervals.

Includes cases with unknown previous TB treatment history.

Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
### Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>38 (37–40)</td>
<td>2.8 (2.7–2.9)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.7 (0.53–0.9)</td>
<td>0.05 (0.04–0.07)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>1 200 (1 100–1 400)</td>
<td>89 (78–102)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>930 (860–1 000)</td>
<td>68 (63–73)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>13 (11–16)</td>
<td>0.98 (0.79–1.2)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>88 (82–95)</td>
<td></td>
</tr>
</tbody>
</table>

### Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>5.7 (4.5–7)</td>
<td>26 (22–30)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>43 000 (34 000–53 000)</td>
<td>8 200 (6 900–9 500)</td>
</tr>
</tbody>
</table>

### TB case notifications 2014

- **Pulmonary, bacteriologically confirmed** 235 704
- **Pulmonary, clinically diagnosed** 526 106
- **Extrapulmonary** 32 348

**Total new and relapse** 819 283

**Previously treated, excluding relapses** 6 872

**Total cases notified** 826 155

Among 819 283 new and relapse cases:

4 164 (<1%) cases aged under 15 years; male:female ratio: 2.3

### Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>45 664 (19%)</td>
<td>17 210 (54%)</td>
<td>62 874</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>5 807</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>2 846</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TB/HIV 2014

- **TB patients with known HIV status** 343 515 (42)
- **HIV-positive TB patients** 5 309 (2)
- **HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)** 3 675 (69)
- **HIV-positive people screened for TB** 423 254
- **HIV-positive people provided with IPT** 2 423 254

### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>(95)</td>
<td>841 999</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>(90)</td>
<td>7 847</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>(82)</td>
<td>4 649</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>(42)</td>
<td>1 906</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>(13)</td>
<td>115</td>
</tr>
</tbody>
</table>

### Laboratories 2014

- **Smear (per 100 000 population)** 0.2
- **Culture (per 5 million population)** 6.7
- **Drug susceptibility testing (per 5 million population)** 1.5
- **Sites performing Xpert MTB/RIF** 654
- **Is second-line drug susceptibility testing available?** Yes, in country

### Financing TB control 2015

- **National TB programme budget (US$ millions)** 340
- % Funded domestically 90%
- % Funded internationally 2%
- % Unfunded 8%

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

* Ranges represent uncertainty intervals.

* Includes cases with unknown previous TB treatment history.

* Includes cases with unknown previous TB treatment history.

* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
Democratic Republic of the Congo  ■  Population 2014  75 million

Estimates of TB burden

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>52 (38–68)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>6.3 (5.7–7.7)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>4.00 (2.10–6.40)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>2.60 (2.20–2.70)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>3.4 (2.7–4.2)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>4.8 (4.3–5.2)</td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burden

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>545 (&lt;1%)</td>
<td>6 135 (75%)</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>442</td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>436</td>
<td></td>
</tr>
</tbody>
</table>

TB case notifications

<table>
<thead>
<tr>
<th>NEW</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>75 631</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>13 494</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>19 566</td>
</tr>
</tbody>
</table>

Total new and relapse 115 795
Previously treated, excluding relapses 1 099
Total cases notified 116 894

Among 75 631 new cases:
3 438 (5%) cases aged under 15 years; male:female ratio: 1.3

Reported cases of RR-/MDR-TB

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>545 (&lt;1%)</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>442</td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>436</td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases registered in 2013</td>
<td>(87)</td>
</tr>
<tr>
<td>Previously treated cases registered in 2013</td>
<td>(66)</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>(64)</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>(64)</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td></td>
</tr>
</tbody>
</table>

Laboratories 2014

<table>
<thead>
<tr>
<th>Smear (per 100 000 population)</th>
<th>Culture (per 5 million population)</th>
<th>Drug susceptibility testing (per 5 million population)</th>
<th>Sites performing Xpert MTB/RIF</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>0.3</td>
<td>0.2</td>
<td>39</td>
</tr>
</tbody>
</table>

Is second-line drug susceptibility testing available? Yes, in and outside country

Financing TB control 2015

| National TB programme budget (US$ millions) | 55 |
| % Funded domestically | 5% |
| % Funded internationally | 50% |
| % Unfunded | 44% |

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

* Ranges represent uncertainty intervals

** Includes cases with unknown previous TB treatment history.

*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
Estimates of TB burden\(^*\) 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>32 (22–43)</td>
<td>33 (23–44)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>5.5 (4.4–6.6)</td>
<td>5.7 (4.6–7)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>190 (160–240)</td>
<td>200 (161–243)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>200 (160–240)</td>
<td>207 (168–230)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>19 (15–23)</td>
<td>19 (15–24)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>60 (49–73)</td>
<td></td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burden\(^*\) 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>1.6 (0.86–2.8)</td>
<td>12 (5.6–21)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>1 300 (700–2 300)</td>
<td></td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW(^a)</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>40 087</td>
<td></td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>41 575</td>
<td></td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>37 930</td>
<td></td>
</tr>
</tbody>
</table>

Total new and relapse 119 592.

Previously treated, excluding relapses

Total cases notified 119 592.

Among 119 592 new cases: 15 917 (13%) cases aged under 15 years, male:female ratio: 1:2.

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>2 405 (6%)</td>
<td>7 682</td>
<td>10 151</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>503</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment(^c)</td>
<td>557</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TB/HIV 2014

|                        | NUMBER (%)| |
|------------------------|-----------||
| TB patients with known HIV status | 89 320 (75) |
| HIV-positive TB patients | 8 670 (10) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)\(^d\) | 3 396 (39) |
| HIV-positive TB patients on antiretroviral therapy (ART)\(^d\) | 3 396 (39) |
| HIV-positive people screened for TB | 341 534 | |
| HIV-positive people provided with IPT | 10 385 | |

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases registered in 2013</td>
<td>(89)</td>
<td>43 863</td>
</tr>
<tr>
<td>Previously treated cases registered in 2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>(83)</td>
<td>271</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Laboratories 2014

|                        | |
|------------------------||
| Smear (per 100 000 population) | 3.1 |
| Culture (per 5 million population) | 0.4 |
| Drug susceptibility testing (per 5 million population) | 0.4 |
| Sites performing Xpert MTB/RIF | 28 |
| Is second-line drug susceptibility testing available? | Yes, in country |

Financing TB control 2015

|                        | |
|------------------------||
| National TB programme budget (US$ millions) | 82 |
| % Funded domestically | 71% |
| % Funded internationally | 42% |
| % Unfunded | 47% |

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

\(^*\) Ranges represent uncertainty intervals.

\(^a\) Includes cases with unknown previous TB treatment history.

\(^b\) Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

\(^c\) ART and IPT data were missing for 3 of Ethiopia’s 11 regions, which in previous years had accounted for about one third of the national totals. In the 8 regions that reported data, 65% of HIV-positive TB patients were on ART.

Data for all years can be downloaded from www.who.int/tb/data
India

Population 2014  1 295 million

Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>220 (150–350) 17 (12–27)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>31 (25–38) 2.4 (2–2.5)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>2 500 (1 700–3 500) 195 (131–271)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>2 200 (2 000–2 300) 167 (156–179)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>110 (96–120) 8.3 (7.4–9.3)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>74 (70–80)</td>
</tr>
</tbody>
</table>

Ranges represent uncertainty intervals.

Includes cases with unknown previous TB treatment history.

Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

TB case notifications 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>754 268 124 679</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>343 032 112 066</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>275 502</td>
</tr>
</tbody>
</table>

Total new and relapse  1 609 547

Previously treated, excluding relapses  74 368

Total cases notified  1 683 915

Among 1 609 547 new and relapse cases:  95 709 (6%) cases aged under 15 years; male:female ratio: 1:9

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>12 795 (2%) 214 209 (69%) 255 897</td>
<td></td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>25 748</td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>24 073</td>
<td></td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>1 243 905</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>171 712</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>44 027</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>9 874</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>91</td>
</tr>
</tbody>
</table>

Laboratories 2014

<table>
<thead>
<tr>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population)</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
</tr>
</tbody>
</table>

Is second-line drug susceptibility testing available?  Yes, in country

Financing TB control 2015

<table>
<thead>
<tr>
<th>TOTAL ($ millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget</td>
</tr>
<tr>
<td>% Funded domestically</td>
</tr>
<tr>
<td>% Funded internationally</td>
</tr>
<tr>
<td>% Unfunded</td>
</tr>
</tbody>
</table>

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Ranges represent uncertainty intervals.

Includes cases with unknown previous TB treatment history.

Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

---

India

Population 2014  1 295 million

Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>220 (150–350) 17 (12–27)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>31 (25–38) 2.4 (2–2.5)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>2 500 (1 700–3 500) 195 (131–271)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>2 200 (2 000–2 300) 167 (156–179)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>110 (96–120) 8.3 (7.4–9.3)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>74 (70–80)</td>
</tr>
</tbody>
</table>

Ranges represent uncertainty intervals.

Includes cases with unknown previous TB treatment history.

Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

TB case notifications 2014

<table>
<thead>
<tr>
<th>NEW*</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>754 268 124 679</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>343 032 112 066</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>275 502</td>
</tr>
</tbody>
</table>

Total new and relapse  1 609 547

Previously treated, excluding relapses  74 368

Total cases notified  1 683 915

Among 1 609 547 new and relapse cases:  95 709 (6%) cases aged under 15 years; male:female ratio: 1:9

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>12 795 (2%) 214 209 (69%) 255 897</td>
<td></td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>25 748</td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>24 073</td>
<td></td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>1 243 905</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>171 712</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>44 027</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>9 874</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>91</td>
</tr>
</tbody>
</table>

Laboratories 2014

<table>
<thead>
<tr>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population)</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
</tr>
</tbody>
</table>

Is second-line drug susceptibility testing available?  Yes, in country

Financing TB control 2015

<table>
<thead>
<tr>
<th>TOTAL ($ millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget</td>
</tr>
<tr>
<td>% Funded domestically</td>
</tr>
<tr>
<td>% Funded internationally</td>
</tr>
<tr>
<td>% Unfunded</td>
</tr>
</tbody>
</table>

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Ranges represent uncertainty intervals.

Includes cases with unknown previous TB treatment history.

Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

---

132 ■ GLOBAL TUBERCULOSIS REPORT 2015

Data for all years can be downloaded from www.who.int/tb/data
**Indonesia**  Population 2014  254 million

### Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>100 (66–150)</td>
<td>41 (24–59)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>22 (13–32)</td>
<td>8.5 (5.2–13)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)b</td>
<td>1 600 (1 300–2 000)</td>
<td>647 (513–797)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>1 000 (700–1 400)</td>
<td>399 (274–546)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)c</td>
<td>63 (41–90)</td>
<td>23 (16–36)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>32 (23–41)</td>
<td></td>
</tr>
</tbody>
</table>

### Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RETREATMENT</th>
<th>TOTALd</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>1.9 (1.4–2.5)</td>
<td>12 (8.1–17)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>5 600 (4 200–7 400)</td>
<td>1 100 (770–1 600)</td>
</tr>
</tbody>
</table>

### TB case notifications 2014

<table>
<thead>
<tr>
<th></th>
<th>NEWc RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>193 321</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>101 991</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>19 653</td>
</tr>
</tbody>
</table>

Total new and relapse 322 806
c
Previously treated, excluding relapses 1 733
c
Total cases notified 324 539
c

### Among 322 806 new and relapse cases:
23 170 (7%) cases aged under 15 years; male:female ratio: 1.4

### Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RETREATMENT TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>1 058 (&lt;1%)</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>1 812</td>
</tr>
<tr>
<td>Patients started on MDR-TB treatmentd</td>
<td>1 284</td>
</tr>
</tbody>
</table>

### TB/HIV 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
<td>15 074 (5)</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
<td>2 355 (16)</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
<td>963 (41)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
<td>624 (26)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
<td></td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
<td></td>
</tr>
</tbody>
</table>

### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>(%) COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>(88) 345 582</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>(64) 1 521</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>(49) 2 438</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>(54) 432</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>(64) 11</td>
</tr>
</tbody>
</table>

### Laboratories 2014

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population)</td>
<td>2.2</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
<td>0.4</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
<td>0.3</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
<td>41</td>
</tr>
</tbody>
</table>

Is second-line drug susceptibility testing available? Yes, in country

### Financing TB control 2015

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget (US$ millions)</td>
<td>133</td>
</tr>
<tr>
<td>% Funded domestically</td>
<td>13%</td>
</tr>
<tr>
<td>% Funded internationally</td>
<td>21%</td>
</tr>
<tr>
<td>% Unfunded</td>
<td>66%</td>
</tr>
</tbody>
</table>

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

b Ranges represent uncertainty intervals.

b The prevalence rate of bacteriologically confirmed TB was 531 (421–655) per 100 000 population, the prevalence rate of clinically diagnosed TB (i.e. smear-negative and culture-negative TB, including all extra-pulmonary cases) was 116 (91–143) per 100 000 population, the prevalence rate of extra-pulmonary TB (a subset of those in the clinically diagnosed category) was 58 (45–75) per 100 000 population.

c Includes cases with unknown previous TB treatment history.

d Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

Data for all years can be downloaded from www.who.int/tb/data

GLOBAL TUBERCULOSIS REPORT 2015  133
Kenya  Population 2014  45 million

Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>9.4 (6.7–12)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>8.1 (6.4–10)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>120 (64–190)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>110 (110–110)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>40 (38–42)</td>
</tr>
</tbody>
</table>

Case detection, all forms (%) 80 (78–82)

Ranges represent uncertainty intervals.

*b Includes cases with unknown previous TB treatment history.

** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

Data for all years can be downloaded from www.who.int/tb/data
Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>18 (12–26)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>37 (29–45)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>150 (80–240)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>150 (120–180)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>85 (65–110)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>39 (31–49)</td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>3.5 (2.2–4.8)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>1 700 (1 100–2 300)</td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>24 430</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>23 455</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>6 276</td>
</tr>
</tbody>
</table>

Total new and relapse 57 773

Previously treated, excluding relapses 497

Total cases notified 58 270

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL^</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>886 (4%)</td>
<td>906 (22%)</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>544</td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment^</td>
<td>482</td>
<td></td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>(%) COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases registered in 2013^</td>
</tr>
<tr>
<td>Previously treated cases registered in 2013</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
</tr>
</tbody>
</table>

Laboratories 2014

| Smear (per 100 000 population) | 1.2 |
| Culture (per 5 million population) | 0.6 |
| Drug susceptibility testing (per 5 million population) | 0.4 |
| Sites performing Xpert MTB/RIF | 24 |
| Is second-line drug susceptibility testing available? | Yes, in country |

Financing TB control 2015

| National TB programme budget (US$ millions) | 29 |
| Funded domestically | 6% |
| Funded internationally | 68% |
| Unfunded | 28% |

Data for all years can be downloaded from www.who.int/tb/data

GLOBAL TUBERCULOSIS REPORT 2015  135

Mozambique  Population 2014  27 million

Data as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

^ Ranges represent uncertainty intervals.

* Includes cases with unknown previous TB treatment history.

% Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

^ Treatment outcomes were available for new pulmonary bacteriologically confirmed cases only.
Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>28 (20–37)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>4.1 (3.3–5.1)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>240 (190–310)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>200 (180–220)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>19 (15–24)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>70 (64–78)</td>
</tr>
</tbody>
</table>

Ranges represent uncertainty intervals.

Includes cases with unknown previous TB treatment history.

Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>5 (3.1–6.8)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>5 600 (3 500–7 700)</td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th>NEW*</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>42 608</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>70 305</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>16 108</td>
</tr>
</tbody>
</table>

Total new and relapse 138 352

Previously treated, excluding relapses 3 605

Total cases notified 141 957

Among 138 352 new and relapse cases: 36 301 (26%) cases aged under 15 years; male:female ratio: 1.6

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>10 295 (24%)</td>
<td></td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>3 495</td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>1 537</td>
<td></td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases registered in 2013</td>
<td>(87) 135 614</td>
</tr>
<tr>
<td>Previously treated cases registered in 2013</td>
<td>(71) 7 147</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>7 147</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>(79) 443</td>
</tr>
</tbody>
</table>

Labsotories 2014

| Smear (per 100 000 population) | 0.9 |
| Culture (per 5 million population) | 0.3 |
| Drug susceptibility testing (per 5 million population) | 0.2 |
| Sites performing Xpert MTB/RIF | 38 |

Is second-line drug susceptibility testing available? Yes, outside country.

Financing TB control 2015

| National TB programme budget (US$ millions) | 36 |
| % Funded domestically | 11% |
| % Funded internationally | 67% |
| % Unfunded | 22% |

Data for all years can be downloaded from www.who.int/tb/data
Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>170 (91–280)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>78 (53–110)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>590 (460–740)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>570 (340–870)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>100 (59–160)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>15 (10–26)</td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>2.9 (2.1–4)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>2 300 (1 700–3 200)</td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>49 825</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>29 460</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>4 764</td>
</tr>
</tbody>
</table>

Total new and relapse 86 464

| Previously treated, excluding relapses | 4 890 |
| Total cases notified | 91 354 |

Among 91 354 new and relapse cases: 5 463 (6%) cases aged under 15 years; male:female ratio: 1.5

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>24 225</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>798</td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>423</td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases registered in 2013 (86)</td>
<td>91 997</td>
<td></td>
</tr>
<tr>
<td>Previously treated cases registered in 2013 (83)</td>
<td>8 404</td>
<td></td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013 (80)</td>
<td>7 481</td>
<td></td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012 (62)</td>
<td>154</td>
<td></td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Laboratories 2014

<table>
<thead>
<tr>
<th>NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100,000 population)</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
</tr>
<tr>
<td>Is second-line drug susceptibility testing available?</td>
</tr>
</tbody>
</table>

Financing TB control 2015

<table>
<thead>
<tr>
<th>NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget (US$ millions)</td>
</tr>
<tr>
<td>% Funded domestically</td>
</tr>
<tr>
<td>% Funded internationally</td>
</tr>
<tr>
<td>% Unfunded</td>
</tr>
</tbody>
</table>

Data as are reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

*Ranges represent uncertainty intervals.

* Includes cases with unknown previous TB treatment history.

* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
**Pakistan**

**Population 2014** 185 million

### Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>48 (11–110)</td>
<td>26 (6–61)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>1.3 (0.76–1.9)</td>
<td>0.68 (0.41–1)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>630 (530–740)</td>
<td>341 (285–402)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>500 (370–650)</td>
<td>270 (201–350)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>6.4 (4.4–8.7)</td>
<td>3.4 (2.4–4.7)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>62 (48–83)</td>
<td></td>
</tr>
</tbody>
</table>

### Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW (%)</th>
<th>RETREATMENT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>3.7 (2.5–5)</td>
<td>18 (13–23)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>9,000 (6,100–12,000)</td>
<td>2,900 (2,100–3,700)</td>
</tr>
</tbody>
</table>

### TB case notifications 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW (%)</th>
<th>RELAPSE (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>122,537</td>
<td>7,420</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>110,320</td>
<td>426</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>57,463</td>
<td>2,211</td>
</tr>
</tbody>
</table>

**Total new and relapse** 308,417

**Previously treated, excluding relapses** 8,160

**Total cases notified** 316,577

Among 308,417 new and relapse cases:

- 27,245 (9%) cases aged under 15 years; male:female ratio: 1.0

### Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW (%)</th>
<th>RETREATMENT (%)</th>
<th>TOTAL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>361 (&lt;1%)</td>
<td>11,685 (72%)</td>
<td>20,143</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>3,243</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>2,662</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TB/HIV 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
<td>10,715 (3)</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
<td>90 (&lt;1)</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
<td>90 (100)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
<td>90 (100)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
<td></td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
<td></td>
</tr>
</tbody>
</table>

### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>(93)</td>
<td>289,376</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>(80)</td>
<td>7,217</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>(81)</td>
<td>37</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>(71)</td>
<td>858</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>(32)</td>
<td>41</td>
</tr>
</tbody>
</table>

### Laboratories 2014

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100,000 population)</td>
<td>0.8</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
<td>0.3</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
<td>0.1</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
<td>42</td>
</tr>
<tr>
<td>Is second-line drug susceptibility testing available?</td>
<td>Yes, in country</td>
</tr>
</tbody>
</table>

### Financing TB control 2015

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget (US$ millions)</td>
<td>50</td>
</tr>
<tr>
<td>% Funded domestically</td>
<td>17%</td>
</tr>
<tr>
<td>% Funded internationally</td>
<td>60%</td>
</tr>
<tr>
<td>% Unfunded</td>
<td>23%</td>
</tr>
</tbody>
</table>

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

* Ranges represent uncertainty intervals

* Includes cases with unknown previous TB treatment history.

* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>10 (9–11)</td>
<td>10 (9.1–11)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.08 (0.055–0.11)</td>
<td>0.08 (0.06–0.11)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>410 (360–470)</td>
<td>417 (360–470)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>290 (250–320)</td>
<td>288 (254–324)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>2.5 (2–3.2)</td>
<td>2.6 (2–3.2)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>85 (76–97)</td>
<td></td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RETREATMENT</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>2 (1.4–2.7)</td>
<td>21 (16–29)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>4 600 (3 300–6 300)</td>
<td>6 500 (4 700–8 700)</td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>92 991</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>139 950</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>4 161</td>
</tr>
</tbody>
</table>

Total new and relapse 243 379
Previously treated, excluding relapses 24 057
Total cases notified 267 436
Among 97 578 new and relapse cases, 12 191 (12%) cases aged under 15 years, male:female ratio: 1.8

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RETREATMENT TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>4 415 (5%)</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>3 000</td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>2 680</td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
<td>53 354 (20)</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
<td>108 (&lt;1)</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
<td>20 (19)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
<td>53 (39)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
<td>2 680</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
<td></td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>(%) COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>90</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>86</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>10</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>10</td>
</tr>
</tbody>
</table>

Laboratories 2014

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population)</td>
<td>2.6</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
<td>1.1</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
<td>0.2</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
<td>84</td>
</tr>
<tr>
<td>Is second-line drug susceptibility testing available?</td>
<td>Yes, in country</td>
</tr>
</tbody>
</table>

Financing TB control 2015

<table>
<thead>
<tr>
<th></th>
<th>USD millions</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget</td>
<td>106</td>
</tr>
<tr>
<td>% Funded domestically</td>
<td>23%</td>
</tr>
<tr>
<td>% Funded internationally</td>
<td>39%</td>
</tr>
<tr>
<td>% Unfunded</td>
<td>37%</td>
</tr>
</tbody>
</table>
Russian Federation | Population 2014 | 143 million

| Estimates of TB burden | 2014 | | | |
|------------------------|------|-----------------|
| NUMBER (thousands) | RATE (per 100 000 population) |
| Mortality (excludes HIV+TB) | 16 (15–16) | 11 (11–11) |
| Mortality (HIV+TB only) | 1.1 (0.83–1.3) | 0.73 (0.58–0.91) |
| Prevalence (includes HIV+TB) | 160 (70–270) | 109 (49–192) |
| Incidence (includes HIV+TB) | 120 (110–130) | 84 (76–93) |
| Incidence (HIV+TB only) | 5.5 (4.5–6.6) | 3.8 (3.1–4.6) |
| Case detection, all forms (%) | RS (77–94) |

| Estimates of MDR-TB burden | 2014 | | | |
|-----------------------------|------|-----------------|
| NEW | RETREATMENT |
| % of TB cases with MDR-TB | 19 (14–25) | 49 (40–59) |
| MDR-TB cases among notified pulmonary TB cases | 15 000 (11 000–19 000) | 24 000 (19 000–29 000) |

| TB case notifications | 2014 | | | |
|-----------------------|------|-----------------|
| Pulmonary, bacteriologically confirmed | 37 296 | 7 982 |
| Pulmonary, clinically diagnosed | 40 894 | 6 753 |
| Extrapulmonary | 8 763 | 652 |
| Total new and relapse | 102 340 |
| Previously treated, excluding relapses | 33 828 |
| Total cases notified | 136 168 |

Among 102 340 new and relapse cases: 3 195 (3%) cases aged under 15 years, male:female ratio: 2.3

| Reported cases of RR-/MDR-TB | 2014 | | | |
|-----------------------------|------|-----------------|
| NEW | RETREATMENT | TOTAL | | |
| Cases tested for RR-/MDR-TB | 31 250 (84%) | 13 925 (28%) | 45 175 |
| Laboratory-confirmed RR-/MDR-TB cases | 15 585 |
| Patients started on MDR-TB treatment | 21 904 |

| TB/HIV | 2014 | | | |
|-----------------------------|------|-----------------|
| TB patients with known HIV status* | 67 625 |
| HIV-positive TB patients | 5 251 |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) |
| HIV-positive TB patients on antiretroviral therapy (ART) |
| HIV-positive people screened for TB |
| HIV-positive people provided with IPT |

| Treatment success rate and cohort size |  | | | |
|-----------------------------|------|-----------------|
| New and relapse cases registered in 2013 | 3 7 |
| Previously treated cases, excluding relapse, registered in 2013 | 14.1 |
| HIV-positive TB cases, all types, registered in 2013 | 10.4 |
| RR-/MDR-TB cases started on second-line treatment in 2012 | 96 |
| XDR-TB cases started on second-line treatment in 2012 | Yes, in country |

| Laboratories | 2014 | | | |
|-----------------------------|------|-----------------|
| Smear (per 100 000 population) | 3.7 |
| Culture (per 5 million population) | 14.1 |
| Drug susceptibility testing (per 5 million population) | 10.4 |
| Sites performing Xpert MTB/RIF | 96 |

| Finacing TB control | 2015 | | | |
|-----------------------------|------|-----------------|
| National TB programme budget (US$ millions) | 1 894 |
| % Funded domestically | 100% |
| % Funded internationally | <1% |
| % Unfunded | 0% |

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

* UN Population Division estimates are lower than the population registered by the Federal State Statistics Service of the Russian Federation.

† Ranges represent uncertainty intervals.

‡ Includes cases with unknown previous TB treatment history.

§ Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

* The reported number of TB patients with known HIV status is for new TB patients in the civilian sector only. It was not possible to calculate the percentage of all TB patients with known HIV status.
South Africa  ■  Population 2014  54 million

Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>24 (22–26)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>72 (58–89)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>360 (210–590)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>450 (400–510)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>270 (240–310)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>68 (61–77)</td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>1.8 (1.4–2.3)</td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>155 473</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>106 482</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>33 522</td>
</tr>
</tbody>
</table>

Total new and relapse 306 166

Previously treated, excluding relapses 12 027

Total cases notified 318 193

Among 306 166 new and relapse cases:
31 977 (10%) cases aged under 15 years; male:female ratio: 1.3

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTALa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>218 231</td>
<td></td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>18 734</td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatmentc</td>
<td>11 538</td>
<td></td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>78</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>69</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>76</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>49</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>20</td>
</tr>
</tbody>
</table>

Laboratories 2014

<table>
<thead>
<tr>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population)</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
</tr>
<tr>
<td>Is second-line drug susceptibility testing available?</td>
</tr>
</tbody>
</table>

Financing TB control 2015

<table>
<thead>
<tr>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget (US$ millions)</td>
</tr>
<tr>
<td>% Funded domestically</td>
</tr>
<tr>
<td>% Funded internationally</td>
</tr>
<tr>
<td>% Unfunded</td>
</tr>
</tbody>
</table>

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
## Estimates of TB burden\(^a\) 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mortality</strong> (excludes HIV+TB)</td>
<td>7.4 (3.9–12)</td>
<td>11 (5.7–18)</td>
</tr>
<tr>
<td><strong>Mortality</strong> (HIV+TB only)</td>
<td>4.5 (2.3–7.4)</td>
<td>6.6 (3.4–11)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>160 (110–220)</td>
<td>236 (161–326)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>120 (61–190)</td>
<td>171 (90–276)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>75 (7.8–24)</td>
<td>22 (12–36)</td>
</tr>
<tr>
<td><strong>Case detection, all forms (%)</strong></td>
<td>59 (36–110)</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Ranges represent uncertainty intervals.

## Estimates of MDR-TB burden\(^a\) 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW(^b)</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>% of TB cases with MDR-TB</strong></td>
<td>2 (1.4–2.8)</td>
<td>19 (14–25)</td>
</tr>
<tr>
<td><strong>MDR-TB cases among notified pulmonary TB cases</strong></td>
<td>1100 (750–1600)</td>
<td>1100 (800–1500)</td>
</tr>
</tbody>
</table>

## TB case notifications 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW(^b)</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>34 394</td>
<td>1 969</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>21 115</td>
<td>0</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>10 244</td>
<td>0</td>
</tr>
</tbody>
</table>

**Total new and relapse**: 67 732

**Previously treated, excluding relapses**: 3 896

**Total cases notified**: 71 618

Among 34 394 new cases:
119 (~1%) cases aged under 15 years; male:female ratio: 2.5

## Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW(^b)</th>
<th>RETREATMENT</th>
<th>TOTAL(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>4 370 (13%)</td>
<td>2 209 (38%)</td>
<td>9 580</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>506</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment(^c)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## TB/HIV 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
<td>50 670 (71)</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
<td>6 831 (13)</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
<td>4 359 (64)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
<td>4 691 (69)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
<td></td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
<td></td>
</tr>
</tbody>
</table>

## Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>(81)</td>
<td>65 867</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>(66)</td>
<td>1 812</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>(67)</td>
<td>7 665</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Laboratories 2014

<table>
<thead>
<tr>
<th></th>
<th>Rate per 100,000 population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear</td>
<td>1.3</td>
</tr>
<tr>
<td>Culture</td>
<td>3.9</td>
</tr>
<tr>
<td>Drug susceptibility testing</td>
<td>1.5</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
<td>14</td>
</tr>
<tr>
<td>Is second-line drug susceptibility testing available?</td>
<td>Yes, in country</td>
</tr>
</tbody>
</table>

## Financing TB control 2015

<table>
<thead>
<tr>
<th></th>
<th>Total budget (US$ millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget</td>
<td>32</td>
</tr>
<tr>
<td>% Funded domestically</td>
<td>52%</td>
</tr>
<tr>
<td>% Funded internationally</td>
<td>11%</td>
</tr>
<tr>
<td>% Unfunded</td>
<td>37%</td>
</tr>
</tbody>
</table>

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

\(^a\) Ranges represent uncertainty intervals

\(^b\) Includes cases with unknown previous TB treatment history.

\(^c\) Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>4.5 (3.2–6.1)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>6.4 (5–8.1)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>60 (33–95)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>61 (53–69)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>28 (24–32)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>72 (64–83)</td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th>NEW RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th>NEW RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
</tr>
<tr>
<td>Extrapulmonary</td>
</tr>
</tbody>
</table>

Total new and relapse 44 187
Previously treated, excluding relapses 1 984
Total cases notified 46 171
Among 44 187 new and relapse cases
3.3% (8%) cases aged under 15 years, male:female ratio: 1.8

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NEW RETREATMENT TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
</tr>
</tbody>
</table>

TB/HIV 2014

| NUMBER (%) |
| TB patients with known HIV status | 43 883 (95) |
| HIV-positive TB patients | 19 612 (45) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) | 19 211 (98) |
| HIV-positive TB patients on antiretroviral therapy (ART) | 15 877 (81) |
| HIV-positive people screened for TB | 729 268 |
| HIV-positive people provided with IPT |

Treatment success rate and cohort size

| (%) COHORT |
| New and relapse cases registered in 2013 | 44 605 |
| Previously treated cases, excluding relapse, registered in 2013 | 2 572 |
| HIV-positive TB cases, all types, registered in 2013 | 16 762 |
| RR-/MDR-TB cases started on second-line treatment in 2012 | 41 |
| XDR-TB cases started on second-line treatment in 2012 | 0 |

Laboratories 2014

| Smear (per 100 000 population) | 3.6 |
| Culture (per 5 million population) | 0.7 |
| Drug susceptibility testing (per 5 million population) | 0.7 |
| Sites performing Xpert MTB/RIF | 74 |
| Is second-line drug susceptibility testing available? Yes, in country |

Financing TB control 2015

| National TB programme budget (US$ millions) | 24 |
| % Funded domestically | 10% |
| % Funded internationally | 69% |
| % Unfunded | 21% |

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
* Ranges represent uncertainty intervals.
+ Includes cases with unknown previous TB treatment history.
$ Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
United Republic of Tanzania

Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>30 (13–54)</td>
<td>5 (26–104)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>28 (15–43)</td>
<td>5 (30–84)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>270 (110–510)</td>
<td>528 (215–979)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>170 (80–290)</td>
<td>327 (155–560)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>62 (29–110)</td>
<td>120 (56–208)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>36 (21–77)</td>
<td></td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>1.1 (0.5–2)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>520 (230–940)</td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>23 583</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>23 380</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>13 600</td>
</tr>
</tbody>
</table>

Total new and relapse | 61 571
Previously treated, excluding relapses | 1 580
Total cases notified | 63 151

Among 61 571 new and relapse cases:
6.463 (10%) cases aged under 15 years, male:female ratio: 1.5

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RETREATMENT TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>9 506 (40%) 882 (34%)</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>516</td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>143</td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
<td>57 612 (91)</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
<td>20 055 (35)</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
<td>19 388 (97)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
<td>16 564 (83)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
<td>525 713</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
<td>23 124</td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>(91)</td>
<td>64 053</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>(79)</td>
<td>1 679</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>(72)</td>
<td>20 320</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>(73)</td>
<td>45</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Laboratories 2014

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population)</td>
<td>1.8</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
<td>0.4</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
<td>59</td>
</tr>
<tr>
<td>Is second-line drug susceptibility testing available?</td>
<td>Yes, in country</td>
</tr>
</tbody>
</table>

Financing TB control 2015

<table>
<thead>
<tr>
<th></th>
<th>($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget (US$ millions)</td>
<td>67</td>
</tr>
<tr>
<td>% Funded domestically</td>
<td>100%</td>
</tr>
<tr>
<td>% Funded internationally</td>
<td>100%</td>
</tr>
<tr>
<td>% Unfunded</td>
<td>100%</td>
</tr>
</tbody>
</table>

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

a Ranges represent uncertainty intervals
b Includes cases with unknown previous TB treatment history.
c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.


total

Data for all years can be downloaded from www.who.int/tb/data
Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>17 (11–23)</td>
<td>18 (12–25)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>1.9 (1.3–2.5)</td>
<td>2.1 (1.4–2.7)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>180 (76–330)</td>
<td>198 (83–362)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>130 (110–150)</td>
<td>140 (116–167)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>7 (5.7–8.5)</td>
<td>7.6 (6.1–9.2)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>77 (65–94)</td>
<td></td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>4 (2.5–5.4)</td>
<td>23 (17–30)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>3,000 (1,900–4,100)</td>
<td>2,100 (1,500–2,600)</td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW*</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>49,938</td>
<td>7,114</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>25,179</td>
<td></td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>18,118</td>
<td></td>
</tr>
</tbody>
</table>

Total new and relapse 100,349

Previously treated, excluding relapses 1,738

Total cases notified 102,087

Among 49,929 new cases:

144 (<1%) cases aged under 15 years, male:female ratio: 3:0

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTALa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>2,756 (6%)</td>
<td>8,511 (96%)</td>
<td>13,829</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>2,198</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatmentb</td>
<td>1,532</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
<td>74,092 (73)</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
<td>3,875 (5)</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
<td>2,936 (76)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
<td>2,827 (73)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
<td>90,592</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
<td></td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>(89)</td>
<td>102,196</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>(71)</td>
<td>4,453</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>(71)</td>
<td>713</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td></td>
<td>0</td>
</tr>
</tbody>
</table>

Laboratories 2014

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100,000 population)</td>
<td>1.1</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
<td>1.2</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
<td>0.1</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
<td>30</td>
</tr>
</tbody>
</table>

Is second-line drug susceptibility testing available? Yes, in and outside country

Financing TB control 2015

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget (US$ millions)</td>
<td>66</td>
</tr>
<tr>
<td>% Funded domestically</td>
<td>10%</td>
</tr>
<tr>
<td>% Funded internationally</td>
<td>17%</td>
</tr>
<tr>
<td>% Unfunded</td>
<td>72%</td>
</tr>
</tbody>
</table>

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

*Ranges represent uncertainty intervals.

*b Includes cases with unknown previous TB treatment history.

*c Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

Viet Nam ■ Population 2014 92 million
Zimbabwe ▷ Population 2014 15 million

<table>
<thead>
<tr>
<th>Estimates of TB burden* 2014</th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>2.3 (1.4–3.4)</td>
<td>15 (9.5–22)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>5.2 (3.2–7.8)</td>
<td>34 (21–51)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>44 (24–71)</td>
<td>292 (158–465)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>42 (29–58)</td>
<td>279 (193–379)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>25 (17–35)</td>
<td>167 (114–229)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>70 (51–100)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Estimates of MDR-TB burden* 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEW</td>
</tr>
<tr>
<td>% of TB cases with MDR-TB</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
</tr>
<tr>
<td>RELAPSE</td>
</tr>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
</tr>
<tr>
<td>Extrapulmonary</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TB case notifications 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEW*</td>
</tr>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
</tr>
<tr>
<td>Extrapulmonary</td>
</tr>
</tbody>
</table>

Total new and relapse cases: 29 653
Previously treated, excluding relapses: 2 363
Total cases notified: 32 016

Among 29 653 new and relapse cases:
2 290 (8%) cases aged under 15 years, male:female ratio: 1.3

<table>
<thead>
<tr>
<th>Reported cases of RR-/MDR-TB 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEW</td>
</tr>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
</tr>
<tr>
<td>RETREATMENT</td>
</tr>
<tr>
<td>TOTAL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TB/HIV 2014</th>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
<td>28 508 (89)</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
<td>19 290 (68)</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
<td>18 200 (94)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
<td>16 522 (86)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
<td>133 997</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
<td>30 420</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment success rate and cohort size</th>
</tr>
</thead>
<tbody>
<tr>
<td>(%), COHORT</td>
</tr>
<tr>
<td>New cases registered in 2013</td>
</tr>
<tr>
<td>Previously treated cases registered in 2013</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laboratories 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population)</td>
</tr>
<tr>
<td>Culture (per 5 million population)</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population)</td>
</tr>
<tr>
<td>Sites performing Xpert MTB/RIF</td>
</tr>
<tr>
<td>Is second-line drug susceptibility testing available?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Financing TB control 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>National TB programme budget (US$ millions)</td>
</tr>
<tr>
<td>% Funded domestically</td>
</tr>
<tr>
<td>% Funded internationally</td>
</tr>
<tr>
<td>% Unfunded</td>
</tr>
</tbody>
</table>

Data as are reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
* Ranges represent uncertainty intervals
* Includes cases with unknown previous TB treatment history.
* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

Data for all years can be downloaded from www.who.int/tb/data